Pharmacokinetic properties of IgG and various Fc fusion proteins in mice

mAbs

Volumn 8, Issue 1, 2016, Pages 120-128

  Unverdorben, Felix ^a   Richter, Fabian ^a   Hutt, Meike ^a   Seifert, Oliver ^a   Malinge, Pauline ^b   Fischer, Nicolas ^b   Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b NOVIMMUNE SA   (Switzerland)

Author keywords

Fc fusion protein; Half life; Immunoglobulin G (IgG); Neonatal Fc receptor (FcRn); Pharmacokinetics

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FC FUSION PROTEIN; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; RECOMBINANT PROTEIN; SINGLE CHAIN DIABODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CLONING; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; MELTING POINT; MOUSE; NONHUMAN; PH; PHARMACOKINETIC PARAMETERS; PHOTON CORRELATION SPECTROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN STABILITY; QUARTZ CRYSTAL MICROBALANCE; SIZE EXCLUSION CHROMATOGRAPHY; ANIMAL; CHO CELL LINE; CRICETULUS; HAMSTER; HEK293 CELL LINE;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; RECOMBINANT FUSION PROTEINS;

EID: 84964502118     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1113360     Document Type: Article

References (31)

1. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011; 22:868-76; PMID:21862310; http://dx.doi.org/10.1016/j.copbio.2011.06.012
2. Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012; 4:1015-28; PMID:22837174; http://dx.doi.org/10.1002/emmm.201201379
3. Levin D, Golding B, Strome SE, Sauna, ZE. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol 2015; 33:27-34; PMID:25488117; http://dx.doi.org/10.1016/j. tibtech.2014.11.001
4. Sockolosky JT, Szoka FC. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev 2015; 91:109-24; PMID:25703189; http://dx.doi.org/10.1016/j.addr.2015.02
5. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. mAbs 2011; 3:415-6; PMID:21785279; http://dx.doi. org/10.4161/mabs.3.5.17334
6. Hombach A, Heuser C, Abken H. Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis. Int J Cancer 2005; 115:241-7; PMID:15688386; http://dx.doi.org/10.1002/ijc.20829
7. Gillies SD, Lan Y, Brunkhorst B, Wong W, Li Y, Lo K. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol Immunother 2002; 51:449-60; PMID: 12202906; http://dx.doi.org/10.1007/s00262-002-0302-6
8. Wu AM. Engineered antibodies for molecular imaging of cancer. Methods 2014; 65:139-47; PMID:24091005; http://dx.doi.org/10.1016/j. ymeth.2013.09.015
9. Kenanova V, Olafsen T, Crow DM, Sundaresanm G, Subbarayanm M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005; 65:622-31; PMID:15695407
10. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23:1137-46; PMID:16151407; http://dx.doi. org/10.1038/nbt1141
11. Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuß N, Müller D, Kontermann RE. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel 2010; 23:827-34; PMID:20817756; http://dx.doi.org/10.1093/protein/gzq058
12. Suzuki T, Ishii-Watanabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184:1968-76; PMID:20083659; http://dx.doi.org/10.4049/jimmunol.0903296
13. Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, Morrison SL. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 2006; 43:1462-73; PMID:16139891; http://dx.doi. org/10.1016/j.molimm.2005.07.032
14. Chester KA, Begent RH, Robson L, Keep P, Pedley RB, Boden JA, Boxer G, Green A, Winter G, Cochet O, Hawkins RE. Phage libraries for the generation of clinically useful antibodies. Lancet 1994; 343:455-6; PMID:7905958; http://dx.doi.org/10.1016/S0140-6736(94)92695-6
15. Stork R, Zettlitz KA, Müller D, Rether M, Hanisch FG, Kontermann RE. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008; 283:7804-12; PMID:18211902; http://dx.doi.org/10.1074/jbc. M709179200
16. Korn T, Müller R, Kontermann RE. Bispecific singlechain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother 2012; 27:99-106; PMID:14770081; http://dx. doi.org/10.1097/00002371-200403000-00003
17. Gehlsen KR, Gong R, Bramhill D, Wiersma DA, Kirkpatrick SA, Wang Y, Feng Y, Dimitrov DS. Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. mAbs 2012; 4:466-74; PMID:22699277; http://dx.doi.org/10.4161/mabs.20652
18. Ying T, Gong R, Ju TW, Prabakaran P, Dimitrov DS. Engineered Fc based antibody domains and fragments as novel scaffolds. Biochim Biophys Acta 2014; 1844:1977-82; PMID:24792384; http://dx.doi.org/10.1016/j.bbapap.2014.04.018
19. Souders CA, Nelson SC, Wang Y, Crowley AR, Klempner MS, Thomas W Jr. A novel in vitro assay to predict neonatal Fc receptor-mediated human Igg halflife. mAbs 2015; 7:912-21; PMID:26018774; http://dx.doi.org/10.1080/19420862.2015.1054585
20. Wang W, Lu P, Fang Y, Hamuro L, Pittmann T, Carr B, Hochman J, Preksaritanont T. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metabol Disp 2011; 39:1469-77; PMID:21610128; http://dx.doi.org/10.1124/dmd.111.039453
21. Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci USA 2015; 112:5997-6002; PMID:25918417; http://dx.doi.org/10.1073/pnas.1408766112
22. Solá RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 2009; 98:1223-45; PMID:18661536; http://dx.doi.org/10.1002/jps.21504
23. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, Hattori K. Reducing elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385-92; PMID:20159773; http://dx. doi.org/10.1093/protein/gzq009
24. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23:1283-8; PMID:16186811; http://dx.doi.org/10.1038/nbt1143
25. Swiercz R, Chiguru S, Tahmasbi A, Ramezani SM, Hao G, Challa DK, Lewis MA, Kulkarni PV, Sun X, Ober RJ, Mason RP, Ward ES. Use of Fc-engineered antibodies as clearing agents to increase contrast during PET. J Nucl Med 2014; 55:1204-7; PMID:24868106; http://dx.doi.org/10.2967/jnumed.113.136481
26. Lencer WI, Blumberg RS. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol 2005; 15:5-9; PMID:15653072; http://dx.doi. org/10.1016/j.tcb.2004.11.004
27. Ward ES, Devanaboyina SC, Ober RJ. Targeting FcRn for the modulation of antibody dynamics. Mol Immunol 2015; 67:131-41; PMID:25766596; http://dx.doi.org/10.1016/j.molimm.2015.02.007
28. Gurbaxani B, Dostalek M, Garnder I. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol 2013; 56:660-74; PMID:23917469; http://dx.doi.org/10.1016/j.molimm.2013.05.008
29. Proetzel G, Wiles MV, Roopenian DC. Genetically engineered humanized mouse models for preclinical antibody studies. BioDrugs 2014; 28:171-80; PMID:24150980; http://dx.doi.org/10.1007/s40259-013-0071-0
30. Magistrelli G, Maline P, Anceriz N, Desmurs M, Venet S, Calloud S, Daubeuf B, Kosco-Vilbois M, Fischer N. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J Immunol Meth 2012; 375:20-9; PMID:21939661; http://dx.doi.org/10.1016/j. jim.2011.09.002
31. Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282:12650-60; PMID:17347147; http://dx.doi.org/10.1074/jbc. M700820200